Business·Industry

"Most of North American ESS Production Capacity Secured Through 2028… Discussions Underway for Additional Orders" – LG Corp. Conference Call

JAEMIN SONG
2026-11-03 10:34:33
[Edaily Reporter JAEMIN SONG ] "Customer demand for batteries produced locally in North America is surging. Policy factors favorable to non-PFE companies are also having an impact.

Based on currently planned production capacity, most of the volume through 2028 has already been secured, and the company is actively discussing orders with customers, focusing on volumes beyond that date.

Customers currently in supply discussions include not only existing power grid and utility companies but also demand for energy storage systems (ESS) for AI data centers facilitated by these companies, as well as direct purchase demand from hyperscalers.

As projected demand exceeds available production capacity, the company plans to efficiently utilize its remaining production capacity going forward, focusing on projects of high strategic importance."

…LG Energy Solution Q3 2026 Conference Call

LG Energy Solution’s Wroclaw plant in Poland. (Photo: LG Energy Solution)

Economy

Corporation

IT·Science

Economy

"Strengthening Local Production in Europe… Expectations for Growing Demand for Non-Chinese Batteries" - LG Corp. Conference Call

"Although the policy direction in Europe has not yet been finalized, according to the IAA’s proposed amendments, foreign direct investment and localization requirements are expected to be further stre…
2026-11-03 10:59:17

Corporation

"ESS Order Backlog Reaches 160 GWh… First Direct Supply Contract Signed with a Big Tech Company" - LG Corp. Conference Call

"In the ESS business, the company has strengthened its market position in the AI data center sector by securing additional projects from existing utility grid customers and, for the first time, signin…
2026-11-03 10:17:55

IT·Science

LGCHEM,LTD Expands Technology Export Agreement for New Drug to Treat Rare Obesity to 1.15 Trillion

LGCHEM,LTD(051910)has expanded the value of its technology export agreement with U.S.-based Rhythm Pharmaceuticals for the rare obesity treatment “Vivamelagon” from the original $305 million (approxim…
2026-11-03 11:21:02